-+ 0.00%
-+ 0.00%
-+ 0.00%

PharmaEssentia to Participate in Upcoming Jefferies and Citi Healthcare Conferences

Barchart·11/02/2026 07:37:00
Listen to the news

PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that members of its management team will participate in the following investor conferences:

Jefferies London Healthcare Conference
Date: November 16-19, 2026
Location: London, United Kingdom

Citi’s 2026 Global Healthcare Conference
Date: December 1-3, 2026
Location: Miami, Florida

Management will be available for investor meetings at both conferences. Investors interested in meeting with management should contact their Jefferies or Citi representative.

About PharmaEssentia
PharmaEssentia USA Corporation, located in Burlington, Massachusetts, is a subsidiary of PharmaEssentia Corporation (TWSE: 6446). PharmaEssentia Corporation, headquartered in Taipei, Taiwan, is a global and rapidly growing biopharmaceutical innovator. Leveraging deep expertise and proven scientific principles, PharmaEssentia aims to deliver effective new biologics for challenging diseases in the areas of hematology, oncology, and immunology with one approved product and a diversifying pipeline. Founded in 2003 by a team of Taiwanese-American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies, today PharmaEssentia is expanding its global presence with operations in the U.S., Japan, China, and Korea, along with a world-class biologics production facility in Taichung, Taiwan. For more information about PharmaEssentia USA, visit the website, LinkedIn or X (formerly Twitter).

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.